Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer

Purpose: Patients with metastatic prostate cancer are increasingly presenting with treatment-resistant, androgen receptor–negative/low (AR−/Low) tumors, with or without neuroendocrine characteristics, in processes attributed to tumor cell plasticity. This plasticity has been modeled by Rb1/p53 knockdown/knockout and is accompanied by overexpression of the pluripotency factor, Sox2. Here, we explore the role of the developmental transcription factor Sox9 in the process of prostate cancer therapy response and tumor progression. Experimental Design: Unique prostate cancer cell models that capture AR−/Low stem cell–like intermediates were analyzed for features of plasticity and the functional role of Sox9. Human prostate cancer xenografts and tissue microarrays were evaluated for temporal alterations in Sox9 expression. The role of NF-κB pathway activity in Sox9 overexpression was explored. Results: Prostate cancer stem cell–like intermediates have reduced Rb1 and p53 protein expression and overexpress Sox2 as well as Sox9. Sox9 was required for spheroid growth, and overexpression increased invasiveness and neural features of prostate cancer cells. Sox9 was transiently upregulated in castration-induced progression of prostate cancer xenografts and was specifically overexpressed in neoadjuvant hormone therapy (NHT)–treated patient tumors. High Sox9 expression in NHT-treated patients predicts biochemical recurrence. Finally, we link Sox9 induction to NF-κB dimer activation in prostate cancer cells. Conclusions: Developmentally reprogrammed prostate cancer cell models recapitulate features of clinically advanced prostate tumors, including downregulated Rb1/p53 and overexpression of Sox2 with Sox9. Sox9 is a marker of a transitional state that identifies prostate cancer cells under the stress of therapeutic assault and facilitates progression to therapy resistance. Its expression may index the relative activity of the NF-κB pathway.

[1]  Dong Lin,et al.  The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications , 2018, GigaScience.

[2]  Jian Ning,et al.  SOX9 is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition , 2018, Oncotarget.

[3]  S. C. Sahinalp,et al.  Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. , 2017, European urology.

[4]  A. Atala.  Re: Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance. , 2017, The Journal of urology.

[5]  M. Rubin,et al.  Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. , 2017, Cancer discovery.

[6]  Henry W. Long,et al.  Embryonic transcription factor SOX9 drives breast cancer endocrine resistance , 2017, Proceedings of the National Academy of Sciences.

[7]  C. Pan,et al.  REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer , 2017, Scientific Reports.

[8]  C. Collins,et al.  Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance , 2017, Oncotarget.

[9]  E. Corey,et al.  Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment , 2017, International journal of cancer.

[10]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[11]  S. Jiang,et al.  Epigenetic Switch between SOX2 and SOX9 Regulates Cancer Cell Plasticity. , 2016, Cancer research.

[12]  Rensheng Wang,et al.  Triptolide Combined with Radiotherapy for the Treatment of Nasopharyngeal Carcinoma via NF-κB-Related Mechanism , 2016, International journal of molecular sciences.

[13]  H. He,et al.  SOX9 drives WNT pathway activation in prostate cancer. , 2016, The Journal of clinical investigation.

[14]  Wendy W Y Choi,et al.  Exosomes confer pro-survival signals to alter the phenotype of prostate cells in their surrounding environment , 2016, Oncotarget.

[15]  Robert H. Bell,et al.  The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. , 2015, Cell reports.

[16]  K. McVary,et al.  Contemporary Incidence and Mortality Rates of Neuroendocrine Prostate Cancer. , 2015, Anticancer research.

[17]  M. Ghert,et al.  The Epigenetic Regulation of SOX9 by miR‐145 in Human Chondrosarcoma , 2015, Journal of cellular biochemistry.

[18]  R. Matusik,et al.  Inhibition of NF-kappa B signaling restores responsiveness of castrate resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor variants expression , 2014, Oncogene.

[19]  C. Nelson,et al.  Androgen-Targeted Therapy-Induced Epithelial Mesenchymal Plasticity and Neuroendocrine Transdifferentiation in Prostate Cancer: An Opportunity for Intervention , 2014, Front. Oncol..

[20]  Chunhong Yan,et al.  Determinants of Gli2 co‐activation of wildtype and naturally truncated androgen receptors , 2014, The Prostate.

[21]  R. Matusik,et al.  SOX2 expression in the developing, adult, as well as diseased prostate , 2014, Prostate Cancer and Prostatic Disease.

[22]  R. Ferraldeschi,et al.  Evolution of androgen receptor targeted therapy for advanced prostate cancer , 2014, Nature Reviews Clinical Oncology.

[23]  J. Luo,et al.  Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects , 2014, Oncogene.

[24]  H. Kondoh,et al.  Sox proteins: regulators of cell fate specification and differentiation , 2013, Development.

[25]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[26]  Lesley A. Mathews,et al.  Epigenetic Regulation of SOX9 by the NF‐κB Signaling Pathway in Pancreatic Cancer Stem Cells , 2013, Stem cells.

[27]  M. Rubin,et al.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. , 2013, Neoplasia.

[28]  A. Alva,et al.  The changing natural history of metastatic prostate cancer. , 2013, Cancer journal.

[29]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[30]  M. Gerstein,et al.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.

[31]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[32]  T. H. van der Kwast,et al.  [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. , 2011, Actas urologicas espanolas.

[33]  Shao-Cong Sun,et al.  Non-canonical NF-κB signaling pathway , 2011, Cell Research.

[34]  J. Cuzick,et al.  SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. , 2010, Cancer research.

[35]  U. Chung,et al.  Transcriptional induction of SOX9 by NF-kappaB family member RelA in chondrogenic cells. , 2009, Osteoarthritis and cartilage.

[36]  R. Matusik,et al.  The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. , 2008, Cancer research.

[37]  A. Thomson,et al.  Prostate development and pathogenesis. , 2008, Differentiation; research in biological diversity.

[38]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[39]  Tao Zhang,et al.  SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. , 2007, Cancer research.

[40]  P. Trainor,et al.  Neural crest stem and progenitor cells. , 2006, Annual review of cell and developmental biology.

[41]  D. Ghosh,et al.  Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.

[42]  C. Korch,et al.  Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.

[43]  John Anderson,et al.  The role of antiandrogen monotherapy in the treatment of prostate cancer , 2003, BJU international.

[44]  A. Shabsigh,et al.  Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells * , 2001, The Prostate.

[45]  R. Taylor,et al.  Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. , 2001, Biochimica et biophysica acta.

[46]  E. Bröcker,et al.  Differential expression of Rel/NF-κB and octamer factors is a hallmark of the generation and maturation of dendritic cells , 2000 .

[47]  E. Bröcker,et al.  Differential expression of Rel/NF-kappaB and octamer factors is a hallmark of the generation and maturation of dendritic cells. , 2000, Blood.

[48]  A. Shabsigh,et al.  Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. , 1999, The Journal of urology.

[49]  P. Ricciardi-Castagnoli,et al.  Brief Definitive Report Dendritic Cell Survival and Maturation Are Regulated by Different Signaling Pathways , 2022 .

[50]  C. Olsson,et al.  Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. , 1997, Urologic oncology.

[51]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[52]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[53]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.